Stable compositions of pegylated carfilzomib compounds
The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.
1. A pharmaceutical composition comprising
(a) a pegylated carfilzomib compound in an amount ranging from 100 mg to 3000 mg; and
(b) 10 mM glutamate, 2% w/v sucrose, and 4% w/v mannitol, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, and 0.006% w/v polysorbate 80, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, and 0.05% w/v pluronic F68, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, 0.5% w/v lysine and 0.006% w/v polysorbate 80, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, 0.8% w/v lysine and 0.006% w/v polysorbate 80, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, 0.5% w/v arginine and 0.006% w/v polysorbate 80, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, 0.8% w/v arginine and 0.006% w/v polysorbate 80.
2. The pharmaceutical composition of claim 1 wherein the pegylated carfilzomib compound has a structure of formula I
or a pharmaceutically acceptable salt thereof, wherein
R 1 is C 1-10 alkyl or C 3-7 cycloalkyl;
each R 2 , independently, is C 1-6 alkyl, —OCH 3 or halogen;
o is an integer selected from 0, 1, 2 or 3;
linker is a moiety having the structure of
wherein R 3 is H or CH 3 ;
n is an integer selected from 1, 2, 3 or 4;
p is an integer selected from 0, 1, 2, 3 or 4;
q is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8 or 9;
r is an integer selected from 0, 1, 2, 3, 4 or 5; and
PEG is a polyethylene glycol polymeric moiety having a molecular weight ranging from about 500 to about 20,000.
3. The composition of claim 2 , wherein the linker is a moiety having the structure of
wherein R 3 is H or CH 3 ;
q is 4; and
r is 2.
4. The composition of claim 1 , wherein the pegylated carfilzomib compound has the structure of
5. The composition of claim 1 , wherein the pegylated carfilzomib compound has the structure of
6. The pharmaceutical composition of claim 1 , wherein the composition is a frozen formulation, wherein the pH of the formulation is in the range from 5.0 to 8.0.
7. The pharmaceutical composition of claim 1 , wherein the composition is a dry lyophilized formulation.
8. The pharmaceutical composition of claim 1 wherein when the composition is dissolved in an amount of water to achieve about 10 mg/mL of the pegylated carfilzomib compound, the pH of the composition is about 5.0.
9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises the pegylated carfilzomib compound in an amount ranging from 150 mg to 2000 mg.
10. The pharmaceutical composition of claim 1 wherein the composition further comprises hyaluronidase.
11. The pharmaceutical composition of claim 10 wherein the hyaluronidase is present in an amount of about 2000 units/mL.
12. The pharmaceutical composition of claim 1 that does not contain a cyclodextrin.
13. The pharmaceutical composition of claim 7 wherein the lyophilized formulation when dissolved in 1.0 ml of water at room temperature provides a clear solution within a time period of about 3 minutes.
14. The pharmaceutical composition of claim 1 that is administered parenterally by infusion or injection.
15. The pharmaceutical composition of claim 1 that is administered intravenously by infusion or injection.
16. The pharmaceutical composition of claim 1 that is administered by sub-cutaneous injection.
17. A method of treating cancer comprising administering to a patient in need thereof, a therapeutically effective amount of the pharmaceutical composition of claim 1 .
18. The method of claim 17 wherein the cancer is multiple myeloma.
19. The method of claim 18 wherein the multiple myeloma is relapsed, refractory or relapsed and refractory multiple myeloma.
20. The method of claim 18 wherein the multiple myeloma is newly diagnosed multiple myeloma.
21. A process of making the pharmaceutical composition of claim 1 for the treatment of multiple myeloma, the process comprising the step of (a) combining a pegylated carfilzomib compound in an amount effective to treat multiple myeloma with
10 mM glutamate, 2% w/v sucrose, and 4% w/v mannitol, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, and 0.006% w/v polysorbate 80, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, and 0.05% w/v pluronic F68, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, 0.5% w/v lysine and 0.006% w/v polysorbate 80, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, 0.8% w/v lysine and 0.006% w/v polysorbate 80, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, 0.5% w/v arginine and 0.006% w/v polysorbate 80, or
10 mM glutamate, 2% w/v sucrose, 4% w/v mannitol, 0.8% w/v arginine and 0.006% w/v polysorbate 80; and
(b) mixing the combination to provide a clear solution.